Drug Development Strategies in China
In the podcast, Kent Thoelke, Executive Vice Presdient, Scientific & Medical Affairs for PRA, discuss parallel drug development strategies in China, the nuances of the regulatory market there, as well as best practices.
Drug approval strategies for China have fallen into one of two camps over the past decade. On one side are a number of sponsors that started doing business in China in the 1990s and even earlier. These early adopters know China well. They know its relationship-based culture, they know its regulatory climate and nuances. This insider knowledge allows them to develop domestic Chinese approval strategies in conjunction with their global strategies and do well on both sides.
But most pharma and biotech firms are relative newcomers to the Chinese market and aren't aware that the regulatory climate has changed dramatically in recent years. Companies that do not have a physical presence in China may not have noticed, but SFDA approval times for Clinical Trials Approvals have dropped to between seven and nine months for small molecules. The 12-month approval that was once a miracle of speed has now become the limit of acceptability.
There are also opportunities in China for sponsors that have not yet completed Phase II trials to create a similar parallel approval strategy. They may not have the final details such as the final dosing to be used, but it is possible to file a CTA for Phase III based on the most current early phase results. This more limited parallel submission strategy can shave several months from the final approval time in China.
Driving Diversity with the Integrated Research Model
October 16th 2024Ashley Moultrie, CCRP, senior director, DEI & community engagement, Javara discusses current trends and challenges with achieving greater diversity in clinical trials, how integrated research organizations are bringing care directly to patients, and more.
AI in Clinical Trials: A Long, But Promising Road Ahead
May 29th 2024Stephen Pyke, chief clinical data and digital officer, Parexel, discusses how AI can be used in clinical trials to streamline operational processes, the importance of collaboration and data sharing in advancing the use of technology, and more.
Zerlasiran Achieves Significant Sustained Reduction in Lipoprotein(a) Levels with Infrequent Dosing
November 20th 2024Zerlasiran, a novel siRNA therapy, demonstrated over 80% sustained reductions in lipoprotein(a) levels with infrequent dosing in the Phase II ALPACAR-360 trial, highlighting its potential as a safe and effective treatment for patients at high risk of cardiovascular disease.
